Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Comment by postie1on Nov 21, 2020 9:36am
136 Views
Post# 31946675

RE:RE:RE:RE:Investors Mislead

RE:RE:RE:RE:Investors MisleadBest i can make of things is that Vm has not ceased that letter of intent but has put it on hold until after the Covid is done so work can resume to see how viable it is.
My biggest concern is the delay on the Iodine property because of law suit that should be settled in 1st quarter 2021. That should not stop the manufacturing of Iodine contrast but the earth to earth is where the best bang for their dollar is. 
I am interested in the financing with the intent to hold down share dilution
VM just needs the approvals to get the ball rolling to see what is going to happen. for some odd reason I think the HC and FDA along with the financing release may be 1 release or follow each other very closely. I would be very surprised if some of this stuff is not very close to being done or already done.
Bullboard Posts